Skip to main content
DRMA logo

Dermata Therapeutics, Inc. (DRMA) Stock Price & Analysis

Dermata Therapeutics, Inc. (DRMA) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $0.532 (-4.66%), as of the Nov 19, 2026 trading session; market cap $2.62M.

Educational signal · not a buy or sell recommendation · How to read this

$0.532 −$0.026 (-4.66%) Market Cap $2.62M

Dermata Therapeutics, Inc. · DRMA

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing pharmaceutical products for medical and aesthetic skin conditions.

Price as of Nov 19, 2026

Key Statistics

20 of 100

MoonshotScore v2 · Dermata Therapeutics (DRMA)

Weak
Business Quality Poor (11)
Financial Safety Strained (37)
Valuation Fair (64)
Growth Durability Flat (46)
Momentum Slipping (21)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality and a strained balance sheet, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Slipping.

  • EPS beat 0 of the last 4 reports
  • Altman Z -20.53 · Piotroski F 3

Holding back: weak fundamentals, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DRMA (57 recorded, newest six shown)
RecordedScoreBand
23Weak
19Weak
19Weak
19Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.532
Change on the day-4.66%
52-week range$0.532 – $4.66
Market capitalisation$2.62M—
Price / earnings (trailing)-0.25
Shares traded on the day42.5K

Price & events

Other perspectives

Council score for Dermata Therapeutics (DRMA): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Moderate
Growth Durability Neutral
Momentum Weak

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
ROE Negative
Gross Margin Moderate

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Dermata Therapeutics (DRMA), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Dermata Therapeutics, Inc. (DRMA) is the company analyzed here. It employs 9 people and is led by Gerald T. Proehl. The market values it at $2.62M.

2 · Latest results

What do the latest results show for Dermata Therapeutics (DRMA)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Dermata Therapeutics (DRMA)?

Short answer · as of

What is holding it back is weak fundamentals, weak price trend. The distress and quality screens read Altman Z -20.53 · Piotroski F 3. Trailing ratios: current ratio 2.36.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -20.53 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Dermata Therapeutics (DRMA)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $100,000 · EPS -2.17 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for DRMA.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Dermata Therapeutics compare with its peers?

Short answer

Dermata Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
AbbVie Inc. (ABBV) Named competitor$286.01 Nov 18, 2026$506B83 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
Dermata Therapeutics (DRMA) — this page$0.532$2.62M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$100,000
EPS estimate
$-2.17

Measured against a quoted price of $0.532 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 16, 2026

Transactions
10
Identified insiders
3
Purchases
0
Sales
1
Other transactions
9

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DRMA in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DRMA in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Dermata Therapeutics (DRMA)?

Read these with our analysis →

Common Questions About DRMA

These answers are editorial: 1 of these 9 answers is drawn from the DRMA research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for DRMA?

DRMA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is DRMA a good stock to buy?

Stock Expert AI does not rate DRMA buy, sell or hold. Dermata Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the DRMA stock price today?

The last price recorded for Dermata Therapeutics, Inc. (DRMA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for DRMA?

The primary risks for Dermata Therapeutics include the inherent uncertainties of clinical trials, as unfavorable results could significantly impact the company's prospects.

What are the key factors to evaluate for DRMA?

Dermata Therapeutics, Inc. (DRMA) holds a MoonshotScore in the low range. Expansion into New Therapeutic Areas: Dermata has the opportunity to expand its pipeline beyond its current focus on acne, rosacea, psoriasis, hyperhidrosis, and aesthetic conditions. Not financial advice.

How frequently does DRMA data refresh on this page?

DRMA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven DRMA's recent stock price performance?

Dermata Therapeutics, Inc. (DRMA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on specific dermatological conditions allows for targeted research and development. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider DRMA overvalued or undervalued right now?

Dermata Therapeutics, Inc. (DRMA) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research DRMA before investing?

Before investing in Dermata Therapeutics, Inc. (DRMA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 7 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.